

## Anat Naschitz

[Anat Naschitz](#) is a life science investor and entrepreneur, with 27 years of experience across biotech, pharma, digital health and medical devices.

Anat co-founded and co-led [OrbiMed](#) Israel, an Israel focused VC fund and part of the leading, \$20bn global healthcare investment firm, and was previously with [Apax](#), the €60bn private equity firm, where she started her investment career. Previously Anat was an Associate Partner with [McKinsey](#) in London, where she advised the world's preeminent pharmaceutical companies on strategy, acquisitions and spinouts.

Throughout her career Anat has founded companies and nurtured them through success. Examples include successful spinouts such as [89bio](#) (Nasdaq:ETNB), developing a likely best in class therapeutic for NASH, which she co-founded and spun out of Teva, taking it public on Nasdaq 18 months post creation, currently trading at \$1bn; [Sobi](#), which evolved out of a Pharmacia spinout and currently trading at \$7.4bn; and others. She has invested in and nurtured a host of other companies, including [Tytocare](#), a growth stage company commercializing the Home Smart Clinic; [MDClone](#), commercializing a synthetic data platform; [Azura Ophthalmics](#), conducting late stage clinical trials for the root cause of dry eye disease; ForSight Vision 6, developing a truly accommodating IntraOcular Lens with a strategic partner, and others.

Currently, Anat is co-founder and CEO of [9xchange](#), a biopharma marketplace, creating transparency and enabling the ecosystem to monetize pipelines and discover assets whose availability was unknown, through a seamless, initially anonymous, AI-driven process.

Anat earned her MBA at [Insead](#) in France and her LLB at Tel Aviv University.